Vaxxinity, Inc. Class A Common Stock
VAXX
VAXX was delisted on the 8th of May, 2024.
29 hedge funds and large institutions have $48.5M invested in Vaxxinity, Inc. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 8 closing their positions.
27% more capital invested
Capital invested by funds: $38.2M → $48.5M (+$10.3M)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
| 2 |
BlackRock
New York
|
+$777K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$559K |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$414K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$155K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$920K |
| 2 |
ECM
Element Capital Management
New York
|
-$592K |
| 3 |
PML
Prime Movers Lab
Jackson,
Wyoming
|
-$510K |
| 4 |
Millennium Management
New York
|
-$411K |
| 5 |
Two Sigma Investments
New York
|
-$216K |
VAXX Hedge Fund Activity: Q3 2022 in Review
29 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q3 2022, worth a combined $48.5M — up 27% from $38.2M a quarter earlier.
Fund positioning in VAXX was balanced in Q3 2022: 8 funds opened new positions, 8 closed out, 3 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.42M. The largest seller was Marshall Wace, cutting an estimated $920K.
- 29 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $48.5M of Vaxxinity, Inc. Class A Common Stock stock for Q3 2022, up 27% quarter-over-quarter.
- 8 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q3 2022 and 8 closed out, a net change of 0 holders.
- The largest Vaxxinity, Inc. Class A Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $1.42M added.
- The largest Vaxxinity, Inc. Class A Common Stock seller in Q3 2022 was Marshall Wace, an estimated $920K sold.
Based on aggregated 13F filings for Q3 2022.